Hematologists have a significant role in the diagnosis and management of light chain (AL) amyloidosis and are also frequently involved in diagnosing transthyretin (ATTR) and other rarer types of amyloidosis. Recent advances in diagnostic techniques and therapies are dramatically improving patient prognosis. Radionuclide imaging methods are emerging as a highly specific and non-invasive way to diagnose, quantify and monitor organ involvement representing a major advance in amyloidosis management.

This content is only available as a PDF.

Article PDF first page preview

First page of Visualizing amyloidosis: The role of radionuclide imaging in systemic amyloidosis
You do not currently have access to this content.
Sign in via your Institution